Skip to main
VCEL
VCEL logo

Vericel (VCEL) Stock Forecast & Price Target

Vericel (VCEL) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vericel Corp demonstrated robust financial growth, with the burn care franchise increasing by 22% year-over-year to $39.9 million in FY2024, a positive indicator of market demand. The company has strategically expanded its burn care salesforce, which is projected to drive high-single-digit growth in 2025, alongside significant contributions from new product launches such as NexoBrid and MACI arthroscopic. Furthermore, Vericel's management guidance anticipates a gross margin of approximately 73-74% and a continuing upward trajectory in revenue, projecting growth rates of 20-23% for 2025, which positions the company favorably for sustained financial performance.

Bears say

Vericel Corp's financial outlook appears negative due to multiple factors, including a lower than expected revenue in January, particularly regarding its CNS and NexoBrid products, which deviated from projections. The company experienced a top-line miss in the fourth quarter, reporting $75.4 million, which fell short of earlier estimates of $77.9 million, underscoring ongoing performance challenges. Additionally, risks related to potential recession impacts, competitive dynamics affecting key products, and operational disruptions—particularly in the launch of NexoBrid and MACI—further contribute to a pessimistic view of future growth prospects.

Vericel (VCEL) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vericel (VCEL) Forecast

Analysts have given Vericel (VCEL) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Vericel (VCEL) has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vericel (VCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.